Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency

J Clin Invest. 2024 Feb 20;134(8):e175199. doi: 10.1172/JCI175199.

Abstract

While therapies targeting CD19 by antibodies, chimeric antigen receptor T cells (CAR-T), and T cell engagers have improved the response rates in B cell malignancies, the emergence of resistant cell populations with low CD19 expression can lead to relapsed disease. We developed an in vitro model of adaptive resistance facilitated by chronic exposure of leukemia cells to a CD19 immunotoxin. Single-cell RNA-Seq (scRNA-Seq) showed an increase in transcriptionally distinct CD19lo populations among resistant cells. Mass cytometry demonstrated that CD22 was also decreased in these CD19lo-resistant cells. An assay for transposase-accessible chromatin with sequencing (ATAC-Seq) showed decreased chromatin accessibility at promoters of both CD19 and CD22 in the resistant cell populations. Combined loss of both CD19 and CD22 antigens was validated in samples from pediatric and young adult patients with B cell acute lymphoblastic leukemia (B-ALL) that relapsed after CD19 CAR-T-targeted therapy. Functionally, resistant cells were characterized by slower growth and lower basal levels of MEK activation. CD19lo resistant cells exhibited preserved B cell receptor signaling and were more sensitive to both Bruton's tyrosine kinase (BTK) and MEK inhibition. These data demonstrate that resistance to CD19 immunotherapies can result in decreased expression of both CD19 and CD22 and can result in dependency on BTK pathways.

Keywords: Cancer; Oncology.

MeSH terms

  • Agammaglobulinaemia Tyrosine Kinase
  • Antigens, CD19* / genetics
  • Child
  • Chromatin
  • Humans
  • Immunotherapy, Adoptive
  • Mitogen-Activated Protein Kinase Kinases
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / genetics
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / therapy
  • Receptors, Chimeric Antigen
  • Sialic Acid Binding Ig-like Lectin 2* / genetics
  • Young Adult

Substances

  • Agammaglobulinaemia Tyrosine Kinase
  • Antigens, CD19
  • CD22 protein, human
  • Chromatin
  • Mitogen-Activated Protein Kinase Kinases
  • Receptors, Chimeric Antigen
  • Sialic Acid Binding Ig-like Lectin 2